X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · IEX Real-Time Price · USD
0.759
+0.011 (1.47%)
At close: Jul 19, 2024, 4:00 PM
0.720
-0.039 (-5.14%)
Pre-market: Jul 22, 2024, 7:33 AM EDT
X4 Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 3.67, with a low estimate of 1.00 and a high estimate of 5.00. The average target predicts an increase of 383.53% from the current stock price of 0.76.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for XFOR stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 1 | 1 | 1 |
| Buy | 3 | 1 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 5 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +558.76% | Jun 28, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $5 | Buy | Reiterates | $5 | +558.76% | May 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +558.76% | Apr 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +295.26% | Mar 22, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $3 → $1 | Strong Buy → Hold | Downgrades | $3 → $1 | +31.75% | Dec 12, 2023 |
Financial Forecast
Revenue This Year
6.39M
Revenue Next Year
52.30M
from 6.39M
Increased by 718.63%
EPS This Year
-0.56
from -0.57
EPS Next Year
-0.47
from -0.56
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.4M | 171.3M | 308.3M | 488.0M | 278.9M |
| Avg | 6.4M | 52.3M | 110.0M | 186.7M | 209.6M |
| Low | 2.5M | 9.1M | 22.0M | 58.4M | 122.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 2,580.5% | 489.4% | 343.6% | 49.4% |
| Avg | - | 718.6% | 110.3% | 69.7% | 12.2% |
| Low | - | 43.0% | -58.0% | -47.0% | -34.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.22 | -0.05 | 0.36 | 0.68 | 0.39 |
| Avg | -0.56 | -0.47 | -0.22 | 0.00 | 0.09 |
| Low | -0.78 | -0.69 | -0.54 | -0.33 | -0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 18,944.1% |
| Avg | - | - | - | - | 4,400.0% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.